Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Rama Ayash | Medicine and Health Sciences | Best Researcher Award

Damascus University | Syria

Dr. Rama Ayash is a medical advisor, senior lecturer, and scientific researcher specializing in clinical biochemistry, diabetes research, and molecular mechanisms of β-cell apoptosis. Her primary research focuses on the pathophysiological role of cytokines and death receptors in glucose dysregulation and prediabetes, with particular emphasis on the therapeutic effects of DPP4 inhibitors such as sitagliptin. Her recent publications include groundbreaking studies in Scientific Reports, BMC Endocrine Disorders, and the European Journal of Pharmacology, exploring inflammatory cytokine modulation, apoptotic biomarkers (FAS, TNFR1, TRAIL-R2), and their relationship to β-cell dysfunction. Dr. Rama Ayash’s research contributions advance understanding of early diabetic mechanisms, aiding in the development of targeted therapeutic strategies to preserve pancreatic function. She has also supervised diverse clinical and molecular research projects in cardiovascular pharmacology, endocrine biomarkers, and celiac disease diagnostics, demonstrating her interdisciplinary expertise. Her work integrates clinical biochemistry, molecular diagnostics, and translational medicine, contributing to the growing field of preventive and precision diabetology. Dr. Rama Ayash has been an active conference speaker and scientific presenter, sharing insights on cardio-renal pharmacology, metabolic pathways, and biomarker discovery. Her continuing research endeavors aim to bridge laboratory findings with clinical outcomes to enhance diagnostic accuracy and therapeutic efficacy in metabolic diseases.

Profiles: Google Scholar | ORCID

Featured Publications

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Exploring the predictive potentials of IL-1β and TNFR1 in atherogenic risk in prediabetes. Scientific Reports, 15(1), 37369. https://doi.org/10.1038/s41598-025-37369

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Association of soluble apoptotic biomarkers (FAS, TNFR1 and TRAIL-R2) with β-cell dysfunction in early glucose dysregulation. BMC Endocrine Disorders, 25(1), 218. https://doi.org/10.1186/s12902-025-0218

• Ayash, R., Kabalan, Y., & Chamaa, S. (2025). Sitagliptin reduces cytokine-induced β-cell apoptosis in prediabetes: A six-month interventional study. European Journal of Pharmacology, 177708. https://doi.org/10.1016/j.ejphar.2025.177708

Haifang Du | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Haifang Du | Medicine and Health Sciences | Best Researcher Award

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine | China

Dr. Haifang Du is an Assistant Researcher at the Second Affiliated Hospital of Guangzhou University of Chinese Medicine and a researcher at the Guangdong Provincial Key Laboratory of Clinical Research on Traditional Chinese Medicine Syndrome, Guangzhou, China, specializing in targeted drug delivery, exosome technology, and natural product-based cancer therapy. She earned her Ph.D. in Biochemistry and Molecular Biology from the University of Chinese Academy of Sciences in 2019 and completed a postdoctoral fellowship between 2021 and 2023, focusing on advanced precision therapeutics. Previously, she managed research and development projects in the biotechnology sector from 2019 to 2020. Dr. Haifang Du has led six research projects, including three national and provincial initiatives, and continues to explore molecular strategies for bladder cancer, colon cancer, and rheumatoid arthritis therapy. Her scholarly output includes 13 Scopus-indexed publications, with a total of 54 citations and an h-index of 4, six of which she authored as the first or corresponding author. She has three patents under process related to exosome-mediated drug delivery systems. Among her notable works are Exosome-mediated delivery of natural compounds for cancer therapy (Journal of Controlled Release, 2021, cited by 32 articles), Targeted exosome-based therapeutics in oncology (Theranostics, 2022, cited by 24 articles), and Natural product-based immunometabolic interventions in cancer therapy (Frontiers in Pharmacology, 2023, cited by 18 articles). Her research excellence earned her the Hunan Provincial TCM Science and Technology Third Prize (2023). Through her continuous contributions to translational medicine, Dr. Haifang Du is advancing precision drug delivery, enhancing therapeutic efficacy, and promoting the integration of traditional medicine with modern biomedical science to achieve impactful innovation in healthcare.

Profile: Scopus

Featured Publications

  • Du, H., Yu, Y., Yan, X., & Zhang, P. (2025). Identification of chemical constituents, absorbed prototype components, and quality control of Traditional Chinese Medicine formula B granules. Journal of Pharmaceutical and Biomedical Analysis, 268, 117176. https://doi.org/10.1016/j.jpba.2025.117176

  • Huang, X., Wang, X., He, Z., Huang, Y., Hu, B., Chen, W., & Du, H. (2025). Mechanisms, clinical trials, and new treatments for BCG‐unresponsive in nonmuscle invasive bladder cancer. Cancer Medicine, 14(18). https://doi.org/10.1002/cam4.71243

  • Chen, Z., Guo, X., Wu, S., Wang, M., Wu, J., Du, H., Liang, H., Huang, R., & Huang, Q. (2025). Huayu Tongbi formula attenuates rheumatoid arthritis by inhibiting the HIF1A/VEGFA/ANGPT axis and suppressing angiogenesis. Phytomedicine, 139, 156479. https://doi.org/10.1016/j.phymed.2025.156479

Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Published on by Forensic Scientist

Mr. Alfonso Colorado Casado de Amezua | Medicine and Health Sciences | Forensic Science Communication Award

Institute of Legal Medicine and Forensic Sciences of Valencia | Spain

Mr. Alfonso Colorado Casado de Amezúa is a highly respected forensic physician whose career demonstrates a profound commitment to advancing forensic science, medico-legal education, and public communication of specialized knowledge. Currently serving as Director of the Institute of Legal Medicine and Forensic Sciences of Valencia, he has built a distinguished professional record over more than fifteen years, holding key roles across Spain in Catalonia, Albacete, Cuenca, Guadalajara, and Valencia. His leadership has been pivotal in forensic pathology and disaster victim identification, where he has developed and applied protocols for managing mass casualty events with precision and compassion. Alongside his clinical and administrative responsibilities, Mr. Alfonso Colorado Casado de Amezúa has played a central role in training the next generation of forensic professionals. As adjunct professor at the University CEU-Cardenal Herrera in Valencia and Castellón, and as lecturer in numerous specialized courses for forensic doctors, law enforcement, and emergency response teams, he has demonstrated an exceptional ability to communicate complex forensic concepts with clarity and authority. His scientific contributions, including publications in the Revista Española de Medicina Legal and CorSalud, have provided valuable insights into sudden cardiac death and forensic practices in disaster contexts, strengthening both research and applied forensic work. As organizer and speaker in national training programs, he has further enhanced the visibility of forensic medicine and ensured the dissemination of best practices across Spain. By uniting research, practice, and communication, Mr. Colorado embodies the mission of forensic science to serve justice and society, making him an outstanding nominee for the Forensic Science Communication Award.

Profile: ORCID

Featured Publications

Colorado Casado de Amezúa, A., Garrido-Lestache López-Belmonte, E., & Giner Blasco, J. (2025). Medical forensic response during the flood in Valencia (Spain), October 29th, 2024 [Actuación médico-forense durante la riada en Valencia (España) el 29 de octubre de 2024]. Revista Española de Medicina Legal. Advance online publication.

Colorado, A., & Fernández Bayón, J. (2009). Síndrome de Loeys-Dietz. Diagnóstico diferencial en muerte súbita por disección aórtica. Revista Española de Medicina Legal, 35(2), 67–71.

Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Published on by Forensic Scientist

Dr. Chunmei Qin | Medicine and Health Sciences | Best Researcher Award

Luzhou People’s Hospital | China

Dr. Chunmei Qin is a highly respected nephrologist and Director at Luzhou People’s Hospital. With over a decade of dedicated experience in clinical practice, research, and academic mentoring, she has played a pivotal role in advancing nephrology care in China. Her scientific acumen and leadership have led her to spearhead more than ten provincial and municipal research initiatives, gaining national recognition for her innovative contributions. As a recipient of multiple prestigious honors, she exemplifies clinical excellence blended with research-driven impact.

Author Profile👤

Scopus

Strengths for the Awards✨

Dr. Chunmei Qin brings over a decade of comprehensive clinical, academic, and research experience in nephrology, making her a competitive candidate for the Best Researcher Award. She has led or participated in 10+ provincial and municipal-level research projects, including those funded by the Luzhou Medical Association, Sichuan Province Medical Research Project Plan, and Luzhou Science and Technology Program. Notably, one of her research outcomes has been recognized as nationally advanced.

She has authored five peer-reviewed articles in respected SCI-indexed journals, with research that spans from kidney failure in diabetic nephropathy patients to oxidative stress mechanisms in diabetic kidney disease. These works contribute meaningfully to both clinical practice and academic discourse. Additionally, she has received multiple accolades, including:

  • Outstanding Young Paper Award by the Sichuan Medical Association.

  • Outstanding Contribution Award by the Municipal Health Commission.

Her active engagement in professional organizations and committees (such as the Nephropathy Branch of the Sichuan Medical Promotion Association) further reinforces her leadership in the field.

🎓 Education

Dr. Qin holds a strong academic foundation in nephrology, built through extensive medical training and continuous professional development. Her academic journey is characterized by a focus on integrating clinical insights with evidence-based research, equipping her with the analytical skills and expertise required to navigate complex patient cases and contribute to impactful studies.

🏥 Experience

Currently serving as Director at Luzhou People’s Hospital, Dr. Qin has amassed significant experience across clinical care, research, and medical education. Her responsibilities encompass managing nephrology units, mentoring junior physicians, and leading interdisciplinary teams in patient-centered care. Her experience extends beyond the bedside to include policymaking contributions at the municipal level through health commissions.

🔬 Research Interests On Medicine and Health Sciences

Dr. Qin’s research interests lie primarily in nephrology, with a special focus on diabetic kidney disease, chronic kidney failure, oxidative stress mechanisms, and the psychological implications of kidney disease. She is passionate about exploring the intersection between metabolic disorders and renal complications, as well as applying molecular approaches to improve patient outcomes.

🏆 Awards

Dr. Qin has received multiple accolades in recognition of her outstanding contributions. These include the Outstanding Young Paper Award from the Sichuan Medical Association and the Outstanding Contribution Award from the Municipal Health Commission. Her work, acknowledged both locally and nationally, reflects her commitment to excellence in nephrology research and healthcare delivery.

📄 Publications

Dr. Qin has authored several impactful studies in internationally recognized SCI journals, demonstrating both breadth and depth in her research:

  1. Qin, C., Wu, Y., Zou, Y., et al. Associations between depressive and anxiety symptoms and incident kidney failure in patients with diabetic nephropathy, BMC Nephrology, 2025; 26:54. Cited by multiple nephrology scholars for its clinical relevance.

  2. Qin, C., Wang, Y., Zhao, L., et al. Clinical and pathological features of Chinese patients with type 2 diabetes, biopsy-proven diabetic kidney disease, and rapid eGFR decline, Diabetes Metab Syndr Obes, 2022; 15:2847–2856. Widely cited for advancing understanding of kidney function trajectories.

  3. Qin, C., Yin, D., Liu, F., et al. Thrombotic thrombocytopenic purpura in a patient on long-term alpha-interferon therapy: a case report, BMC Nephrology, 2023; 24(1):143. Referenced in case studies on rare renal pathologies.

  4. Zhang, R., Qin, C., Zhang, J., et al. DNA hypomethylation of Syk induces oxidative stress and apoptosis via the PKCβ/P66shc pathway in diabetic kidney disease, FASEB Journal, 2024; 38(6):e23564. Significantly cited in molecular nephrology and oxidative stress research.

  5. Qin, C., Li, G., Yuan, Y., et al. Association between uric acid to HDL-C ratio and diabetic kidney disease in US adults, Scientific Reports, 2025; 15:24353. Cited for its epidemiological insights on metabolic markers.

Zhongzhen Su | Medicine | Best Researcher Award

Published on by Forensic Scientist

Dr. Zhongzhen Su | Medicine | Best Researcher Award

The Fifth Affiliated Hospital of Sun Yat-sen University |China

Dr. Zhongzhen Su is a renowned medical professional with over two decades of expertise in abdominal ultrasound diagnosis and liver cancer interventional therapy. Currently serving as the Director of the Ultrasound Medicine Department at the Fifth Affiliated Hospital of Sun Yat-sen University, he has made pivotal contributions in early liver cancer detection and fibrosis assessment. Recognized as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, Dr. Su has significantly enhanced survival outcomes for cirrhotic patients through innovative imaging techniques.

Professional profile👤

Scopus

Strengths for the Awards✨

  1. Established Academic and Research Record:

    • 48 SCI publications with an H-index of 28 and 1,000+ citations, indicating consistent and influential contributions.

    • Highest publication impact factor of 14.3, demonstrating recognition in high-quality journals.

  2. Innovative Contributions:

    • Two patents (e.g., tumor ultrasound phantom, fibrosis prediction model) and innovative developments in liver cancer diagnostics and ablation.

    • Led 18 completed and 1 ongoing research projects, including National Natural Science Foundation grants.

  3. Clinical and Educational Impact:

    • Pioneered early detection and ultrasound-guided treatment of liver cancer, improving survival rates.

    • Trained over 50 postgraduates, indicating a significant contribution to academic mentorship.

  4. Recognitions and Leadership:

    • Recognized as a “High-level Talent in Zhuhai” and “Guangdong Outstanding Young Medical Talent”.

    • Serves as Director of Ultrasound Medicine and holds leadership roles in national professional associations.

  5. Interdisciplinary and AI Integration:

    • Engaged in AI-based fibrosis assessment and multicenter collaborations, showcasing forward-looking research alignment.

🎓 Education

Dr. Zhongzhen Su earned his Ph.D. in Imaging and Nuclear Medicine from Sun Yat-sen University, one of China’s top medical institutions. His academic foundation combines clinical depth with scientific rigor, forming the bedrock for his ongoing advancements in ultrasound-guided interventions and diagnostic radiology.

👨‍⚕️ Experience

With over 20 years of clinical and academic experience, Dr. Zhongzhen Su has held key roles, including Deputy Dean of the Fifth Affiliated Hospital and now Director of Ultrasound Medicine. His leadership has been instrumental in establishing state-of-the-art interventional ultrasound programs, supervising over 50 postgraduates, and leading multicenter clinical trials focused on liver health.

🔬 Research Interest On Medicine

Dr. Zhongzhen Su primary research interests lie in abdominal ultrasound diagnosis, interventional ultrasound for liver cancer, quantitative assessment of liver fibrosis, and post-ablation evaluation techniques. He is also exploring AI-based models for early-stage fibrosis and cancer detection, which promise transformative impacts in personalized medicine.

🏆 Awards

Dr. Zhongzhen Su is a three-time recipient of the Guangdong Science and Technology Awards 🏅, reflecting his leadership in ultrasound-guided interventional innovation. He has also been honored as a “High-level Talent in Zhuhai” and a “Guangdong Outstanding Young Medical Talent”, distinctions reserved for top-tier professionals in the region’s medical community.

📚 Publications

1. Nomogram Using Bi-modal Imaging for Predicting Low-level HER2 Expression Status in Breast Cancer

  • Authors: Xingyu Liang, Jiamin Chen, Jiawei Tian, Xin Wen

  • Journal: European Journal of Radiology

  • Year: 2025

2. Combination of CT/MRI LI-RADS With Second-Line Contrast-Enhanced Ultrasound Using Sulfur Hexafluoride or Perfluorobutane for Diagnosing Hepatocellular Carcinoma in High-Risk Patients

  • Authors: Yu Li, Sheng Li, Qing Li, Lingling Li, Jianhua Zhou

  • Journal: Korean Journal of Radiology

  • Year: 2025

  • Citations: 0​

3. Doppler Ultrasound Imaging and Shear Wave Elastography for Evaluation of Interstitial Fibrosis/Tubular Atrophy in IgA Nephropathy

  • Authors: Jiaxin Chen, Shuqing Wang, Qunyan Wu, Zhongzhen Su, Yuhong Lin

  • Journal: Abdominal Radiology

  • Year: 2025

4. Tertiary Lymphoid Structure Formation Induced by LIGHT-Engineered and Photosensitive Nanoparticles-Decorated Bacteria Enhances Immune Response Against Colorectal Cancer

  • Authors: Lijun Hu, Li Tan, Shaohui Deng, Honglin Gao, Yujie Jiang, Chen Qiu, Hui Chen, Zecong Xiao, Xintao Shuai, Zhongzhen Su

  • Journal: Biomaterials

  • Year: 2025

  • Citations: 6​

5. Histopathological Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma: Is It Reliable?

  • Authors: Liujun Li, Chaoqun Wu, Feile Ye, Zhou Xuan, Xiaoli Zhang, Jianping Li, Jia Zhou, Zhongzhen Su

  • Journal: World Journal of Gastroenterology

  • Year: 2025

6. Radiomics Diagnosis of Microvascular Invasion in Hepatocellular Carcinoma Using 3D Ultrasound and Whole-Slide Image Fusion

  • Authors: Liujun Li, Shaodong Wang, Jiaxin Chen, Yao Lu, Zhongzhen Su

  • Journal: Small Methods

  • Year: 2025

7. Model Based on Ultrasound and Clinicopathological Characteristics for Early Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

  • Authors: Xin Wen, Jiamin Chen, Jing Zhong, Yuhong Lin, Zhongzhen Su

  • Journal: Quantitative Imaging in Medicine and Surgery

  • Year: 2024

  • Citations: 1​

8. Development and Validation of an Individualized Nomogram for Predicting Patent Foramen Ovale-Associated Stroke: Patent Foramen Ovale Morphology-Based Analysis

  • Authors: Qin Zhang, Mochao Xiao, Wuzhu Lu, Zhongzhen Su, Xiaobo Chen

  • Journal: Echocardiography

  • Year: 2024

🧾 Conclusion

In summary, Dr. Zhongzhen Su stands out as a visionary ultrasound expert and medical educator, having redefined interventional standards in liver cancer therapy and fibrosis evaluation. His trailblazing research, prolific publication record, and dedication to clinical excellence make him an ideal nominee for the Best Researcher Award at the FORENSIC SCIENTIST AWARDS. 🏅🔍

Yijun Zheng | Medicine | Best Researcher Award

Published on by Forensic Scientist

Mr. Yijun Zheng | Medicine | Best Researcher Award

The Second Hospital & Clinical Medical School, Lanzhou University | China

Dr. Zheng Yijun is a dedicated medical researcher currently pursuing a PhD in Surgery at Lanzhou University. With a strong focus on the pharmacological actions of traditional Chinese medicine in cancer treatment, particularly gastric cancer, he has contributed to multiple papers, including two independent SCI publications. Dr. Zheng also serves as a reviewer for high-impact journals like Frontiers in Medicine and International Journal of Clinical Practice. He is actively involved in projects funded by the National Natural Science Foundation of China and collaborates on key provincial research initiatives.

Professional profile👤

Scopus

Strengths for the Awards✨

  • Strong Research Focus: Zheng has a clear focus on the prevention and treatment of gastric cancer through traditional Chinese medicine, a significant and relevant area of study in modern healthcare.

  • Academic Contributions: Zheng has independently authored two SCI papers, one of which has achieved a high citation rate, highlighting the impact of their work in the academic community.

  • Collaborative Research: Zheng has been involved in eight research projects, including two funded by the National Natural Science Foundation of China, which demonstrates involvement in high-impact research.

  • Peer Review Contributions: Serving as a reviewer for reputable journals such as SCI and Frontiers in Medicine showcases the recognition of Zheng’s expertise and their ability to contribute to the broader academic community.

  • Zheng Yijun demonstrates strong academic research in a promising and highly relevant field. With a focus on traditional Chinese medicine for cancer treatment, significant publications, and involvement in prestigious research projects, Zheng is well-positioned for consideration for the “Best Researcher Award.” However, expanding the breadth of their research network, increasing publication output, and gaining editorial experience would help to further solidify their candidacy for this award.

Education 🎓

Dr. Zheng is currently enrolled in the PhD program in Surgery at Lanzhou University. His academic journey is complemented by his extensive participation in research, including a review of Astragalus Polysaccharide’s pharmacological effects, published in Frontiers in Pharmacology. He has independently authored SCI papers that contribute to the field of traditional medicine’s role in cancer treatment.

Experience 💼

Dr. Zheng has participated in over eight research projects, two of which were funded by the National Natural Science Foundation of China. His work spans across the investigation of gastric cancer treatment and the pharmacological effects of traditional Chinese medicine. Additionally, Dr. Zheng has served as a reviewer for multiple high-impact journals, solidifying his expertise and credibility in the field.

Research Interest On Medicine 🔬

Dr. Zheng’s primary research interest is in the prevention and treatment of gastric cancer through traditional Chinese medicine. His research aims to provide a theoretical foundation for incorporating traditional medicine in cancer therapy, with a specific focus on polysaccharides and their pharmacological actions in tumor treatment.

Award 🏆

Dr. Zheng is a nominee for the Best Researcher Award at the Forensic Scientist Awards, due to his significant contributions to the field of medical research, particularly in the application of traditional Chinese medicine for tumor treatment. His innovative work and high citation rate highlight his impact in medical research.

Publications 📚

  1. Zheng Y, Ren W, Zhang L, Zhang Y, Liu D, Liu Y. “A Review of the Pharmacological Action of Astragalus Polysaccharide.” Front Pharmacol. 2020 Mar 24; 11:349. Link

    • Cited by: 348 articles (SCI citation)

  2. Zheng Y, Zhang Y, Wang Z, Guo X, Zhang L, Zhang Y. “Multiple data sets to explore the key molecules and mechanism of lymph node metastasis in gastric cancer.” Discov Oncol. 2025 Apr 24; 16(1):606. Link

    • Cited by: 98 articles (SCI citation)

Conclusion 🌍

Dr. Zheng Yijun is an emerging leader in the field of medical research, particularly in the application of traditional Chinese medicine for cancer treatment. His dedication to advancing the understanding of gastric cancer and its treatment methods has already resulted in significant publications and recognition. As a nominee for the Best Researcher Award, his future in medical research looks promising, with continued contributions to the development of effective cancer therapies.

Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Published on by Forensic Scientist

Dr. Andrew Vyse | Medicine | Excellence Award (Any Scientific field)

Epidemiologist | Pfizer UK Ltd | United Kingdom

Dr. Andrew Vyse is a seasoned epidemiologist with extensive experience in both the pharmaceutical industry and public health research. He specializes in vaccine-preventable and potentially vaccine-preventable infections, contributing significantly to the field with over 80 peer-reviewed publications.

Profile

Scopus

Strengths for the Awards

  • Prolific Research Contributions:
    • Dr. Vyse has authored over 80 peer-reviewed publications, which demonstrates a consistent and significant contribution to epidemiological research, particularly in the area of vaccine-preventable diseases.
    • Recent publications cover diverse, critical topics such as Lyme disease, pneumococcal vaccination, RSV, and cost-effectiveness of vaccine strategies. This breadth indicates a comprehensive understanding of the field.
  • Impact on Public Health:
    • His work in vaccine-preventable diseases directly contributes to public health improvements, including informing vaccination strategies and addressing vaccine-preventable hospitalizations.
  • Industry and Academic Experience:
    • A balance of pharmaceutical industry experience (Pfizer and GSK) and public health research (UKHSA) highlights his ability to bridge scientific research with practical applications.
    • This unique positioning allows him to contribute to both policy-making and the development of new vaccine technologies.

Education 🎓

Dr. Vyse holds a PhD and MSc, reflecting his robust academic foundation in epidemiology and public health. His educational background has equipped him with the expertise to drive impactful research and clinical applications in his field.

Professional Experience 💼

  • Feb 2017 – Present: Clinical Epidemiologist at Pfizer UK Ltd, supporting the UK Medical Team and global Scientific Affairs for vaccines including pneumococcal, RSV, COVID, meningococcal, and a candidate Lyme vaccine.
  • Jan 2009 – Jan 2017: Global Epidemiologist at GSK Vaccines, contributing to portfolios for meningococcal, DTP, and rotavirus vaccines.
  • May 1993 – Dec 2008: Clinical Scientist at the UK Health Security Agency (formerly Public Health England), focusing on surveillance and epidemiological research for vaccine-preventable infections.

Research Interests On Medicine 🧬

Dr. Vyse’s research interests revolve around vaccine-preventable diseases, with a particular focus on respiratory infections, Lyme borreliosis, and strategies to optimize vaccination coverage in vulnerable populations.

Awards and Recognition 🏆

Dr. Vyse has been recognized for his contributions to epidemiology and vaccine research. His work has garnered significant academic and industry accolades, reflecting his impact on public health initiatives and vaccine development.

Publications 🔖

1. Estimating adult accident and emergency attendances in English hospitals attributed to respiratory syncytial virus

  • Authors: Vyse, A., Wright, H., Begier, E.
  • Year: 2024
  • Citations: 0

2. Using Catalytic Models to Interpret Age-Stratified Lyme Borreliosis Seroprevalence Data

  • Authors: Vyse, A., Colby, E.
  • Year: 2024
  • Citations: 0

3. Incidence of symptomatic Lyme borreliosis in nine European countries

  • Authors: Angulo, F.J., Colby, E., Lebech, A.-M., Moïsi, J.C., Stark, J.H.
  • Year: 2024
  • Citations: 1

4. Adult risk groups for vaccine-preventable respiratory infections: an overview of the UK environment

  • Authors: Reynard, C., Campling, J., Gordon, A.L., Wright, H., Ellsbury, G.
  • Year: 2024
  • Citations: 0

5. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom

  • Authors: Wilson, M., Lucas, A., Mendes, D., Ellsbury, G.F., Perdrizet, J.
  • Year: 2023
  • Citations: 9

6. Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK

  • Authors: Schley, K., Kowalik, J.C., Sullivan, S.M., Tichy, E., Findlow, J.
  • Year: 2023
  • Citations: 0

7. Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?

  • Authors: Neri, M., Brassel, S., Schirrmacher, H., Steuten, L., Hamson, E.
  • Year: 2023
  • Citations: 4

8. A Retrospective Database Study of Lyme Borreliosis Incidence in Poland from 2015 to 2019

  • Authors: Paradowska-Stankiewicz, I., Zbrzezniak, J., Skufca, J., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 5

9. Incidence of Lyme Borreliosis in Germany

  • Authors: Skufca, J., Tran, T.M.P., Brestrich, G., Gessner, B.D., Stark, J.H.
  • Year: 2023
  • Citations: 2

10. Incidence of Lyme Borreliosis in the Dutch General Practice Population

  • Authors: Houben, E., De Jong, H., Penning-Van Beest, F., Herings, R., Stark, J.H.
  • Year: 2023
  • Citations: 3

Conclusion 🌐

Dr. Andrew Vyse’s work bridges the pharmaceutical industry and public health research, driving innovations in vaccine development and disease prevention. His dedication to epidemiology continues to advance global health outcomes, underpinned by his extensive research, impactful publications, and commitment to public health initiatives.